Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUR109 in Advanced Colorectal, Ovarian, and Renal Cancers
NCT06760702Phase 2Terminated
- Sponsor
- Aurigene Pharmaceutical Services Limited
- Start
- Nov 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aur109 in colorectal cancer (CRC), ovarian cancer and renal cell carcinoma (RCC) (3 arms), sponsored by Aurigene Pharmaceutical Services Limited. Primary endpoint: Objective Response Rate and Safety/Tolerability. Started Nov 2024; status: terminated.
02
Drugs
aur109
03
Conditions
colorectal cancer (CRC)ovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06760702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760702.